Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
Treatment of localised prostatic carcinoma.

Hormone research

Schroeder FH.
PMID: 2613214
Horm Res. 1989;32:44-6. doi: 10.1159/000181308.

Treating stage T3 prostatic carcinoma by surgery alone without adjuvant treatment, offers a potential 30% chance of curing these patients. In addition, the surgical approach offers an effective means of identifying patients not amenable to cure by local measures.

Cite
Schroeder FH. Treatment of localised prostatic carcinoma. Horm Res. 1989;32:44-6doi: 10.1159/000181308.
Schroeder, F. H. (1989). Treatment of localised prostatic carcinoma. Hormone research, 3244-6. https://doi.org/10.1159/000181308
Schroeder, F H. "Treatment of localised prostatic carcinoma." Hormone research vol. 32 (1989): 44-6. doi: https://doi.org/10.1159/000181308
Schroeder FH. Treatment of localised prostatic carcinoma. Horm Res. 1989;32:44-6. doi: 10.1159/000181308. PMID: 2613214.
Copy Download .nbib Format: NLM
Making a case "against" focal therapy for intermediate-risk prostate cancer.

World journal of urology

Gontero P, Marra G, Teber D, Shariat S, Albayrak S, Coelho R, Tanguay S, Konety B.
PMID: 32529451
World J Urol. 2021 Mar;39(3):719-728. doi: 10.1007/s00345-020-03303-y. Epub 2020 Jun 11.

INTRODUCTION: Focal therapy (FT) for localized prostate cancer (PCa) is a promising treatment strategy. Although, according to guidelines, it should be regarded as an experimental option, its introduction into clinical practice has occurred at an accelerated speed. It is,...

Cite
Gontero P, Marra G, Teber D, et al. Making a case "against" focal therapy for intermediate-risk prostate cancer. World J Urol. 2020;39(3):719-728doi: 10.1007/s00345-020-03303-y.
Gontero, P., Marra, G., Teber, D., Shariat, S., Albayrak, S., Coelho, R., Tanguay, S., & Konety, B. (2021). Making a case "against" focal therapy for intermediate-risk prostate cancer. World journal of urology, 39(3), 719-728. https://doi.org/10.1007/s00345-020-03303-y
Gontero, Paolo, et al. "Making a case "against" focal therapy for intermediate-risk prostate cancer." World journal of urology vol. 39,3 (2021): 719-728. doi: https://doi.org/10.1007/s00345-020-03303-y
Gontero P, Marra G, Teber D, Shariat S, Albayrak S, Coelho R, Tanguay S, Konety B. Making a case "against" focal therapy for intermediate-risk prostate cancer. World J Urol. 2021 Mar;39(3):719-728. doi: 10.1007/s00345-020-03303-y. Epub 2020 Jun 11. PMID: 32529451.
Copy Download .nbib Format: NLM
Evolution from active surveillance to focal therapy in the management of prostate cancer.

Future oncology (London, England)

Lindner U, Lawrentschuk N, Schatloff O, Trachtenberg J, Lindner A.
PMID: 21675840
Future Oncol. 2011 Jun;7(6):775-87. doi: 10.2217/fon.11.51.

Organ-preserving therapies are widely accepted in many facets of medicine and, more recently, in oncology. For example, partial nephrectomy is now accepted as a preferred alternative over radical nephrectomy for small (up to 4 cm or T1) tumors. Focal...

Cite
Lindner U, Lawrentschuk N, Schatloff O, et al. Evolution from active surveillance to focal therapy in the management of prostate cancer. Future Oncol. 2011;7(6):775-87doi: 10.2217/fon.11.51.
Lindner, U., Lawrentschuk, N., Schatloff, O., Trachtenberg, J., & Lindner, A. (2011). Evolution from active surveillance to focal therapy in the management of prostate cancer. Future oncology (London, England), 7(6), 775-87. https://doi.org/10.2217/fon.11.51
Lindner, Uri, et al. "Evolution from active surveillance to focal therapy in the management of prostate cancer." Future oncology (London, England) vol. 7,6 (2011): 775-87. doi: https://doi.org/10.2217/fon.11.51
Lindner U, Lawrentschuk N, Schatloff O, Trachtenberg J, Lindner A. Evolution from active surveillance to focal therapy in the management of prostate cancer. Future Oncol. 2011 Jun;7(6):775-87. doi: 10.2217/fon.11.51. PMID: 21675840.
Copy Download .nbib Format: NLM
[Cytoreductive prostate surgery as an alternative treatment for advanced prostate cancer].

Ugeskrift for laeger

Borre M.
PMID: 23286764
Ugeskr Laeger. 2012 Dec 10;174(50):3154.

No abstract available.

Cite
Borre M. Cytoreduktiv prostatakirurgi som alternativ behandling ved avanceret prostatacancer. [Cytoreductive prostate surgery as an alternative treatment for advanced prostate cancer]. Ugeskr Laeger. 2012;174(50):3154
Borre, M. (2012). Cytoreduktiv prostatakirurgi som alternativ behandling ved avanceret prostatacancer. [Cytoreductive prostate surgery as an alternative treatment for advanced prostate cancer]. Ugeskrift for laeger, 174(50), 3154.
Borre, Michael. "Cytoreduktiv prostatakirurgi som alternativ behandling ved avanceret prostatacancer." [Cytoreductive prostate surgery as an alternative treatment for advanced prostate cancer]. Ugeskrift for laeger vol. 174,50 (2012): 3154.
Borre M. Cytoreduktiv prostatakirurgi som alternativ behandling ved avanceret prostatacancer. [Cytoreductive prostate surgery as an alternative treatment for advanced prostate cancer]. Ugeskr Laeger. 2012 Dec 10;174(50):3154. Danish. PMID: 23286764.
Copy Download .nbib Format: NLM
Recent trends in surgical treatment of localized prostate cancer.

Clinical prostate cancer

Link BA, Culkin DJ.
PMID: 16197615
Clin Prostate Cancer. 2005 Sep;4(2):130-3. doi: 10.3816/cgc.2005.n.022.

Prostate cancer and its various forms of treatment remain a source of significant controversy and morbidity despite recent advances. In response, there is an increasing trend toward the development of treatments aimed at cancer prevention and at maximizing the...

Cite
Link BA, Culkin DJ. Recent trends in surgical treatment of localized prostate cancer. Clin Prostate Cancer. 2005;4(2):130-3doi: 10.3816/cgc.2005.n.022.
Link, B. A., & Culkin, D. J. (2005). Recent trends in surgical treatment of localized prostate cancer. Clinical prostate cancer, 4(2), 130-3. https://doi.org/10.3816/cgc.2005.n.022
Link, Brian A, and Culkin, Daniel J. "Recent trends in surgical treatment of localized prostate cancer." Clinical prostate cancer vol. 4,2 (2005): 130-3. doi: https://doi.org/10.3816/cgc.2005.n.022
Link BA, Culkin DJ. Recent trends in surgical treatment of localized prostate cancer. Clin Prostate Cancer. 2005 Sep;4(2):130-3. doi: 10.3816/cgc.2005.n.022. PMID: 16197615.
Copy Download .nbib Format: NLM
Words of wisdom. Re: The role of surgery in high-risk localized prostate cancer.

European urology

Van Poppel H.
PMID: 25305786
Eur Urol. 2014 Aug;66(2):387-9. doi: 10.1016/j.eururo.2014.05.020.

No abstract available.

Cite
Van Poppel H. Words of wisdom. Re: The role of surgery in high-risk localized prostate cancer. Eur Urol. 2014;66(2):387-9doi: 10.1016/j.eururo.2014.05.020.
Van Poppel, H. (2014). Words of wisdom. Re: The role of surgery in high-risk localized prostate cancer. European urology, 66(2), 387-9. https://doi.org/10.1016/j.eururo.2014.05.020
Van Poppel, Hendrik. "Words of wisdom. Re: The role of surgery in high-risk localized prostate cancer." European urology vol. 66,2 (2014): 387-9. doi: https://doi.org/10.1016/j.eururo.2014.05.020
Van Poppel H. Words of wisdom. Re: The role of surgery in high-risk localized prostate cancer. Eur Urol. 2014 Aug;66(2):387-9. doi: 10.1016/j.eururo.2014.05.020. PMID: 25305786.
Copy Download .nbib Format: NLM
Re: High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer. Initial Outcomes of a United States Series.

European urology

Macek P, Sanchez-Salas R, Cathelineau X.
PMID: 33308906
Eur Urol. 2021 Apr;79(4):554-555. doi: 10.1016/j.eururo.2020.11.039. Epub 2020 Dec 09.

No abstract available.

Cite
Macek P, Sanchez-Salas R, Cathelineau X. Re: High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer. Initial Outcomes of a United States Series. Eur Urol. 2020;79(4):554-555doi: 10.1016/j.eururo.2020.11.039.
Macek, P., Sanchez-Salas, R., & Cathelineau, X. (2021). Re: High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer. Initial Outcomes of a United States Series. European urology, 79(4), 554-555. https://doi.org/10.1016/j.eururo.2020.11.039
Macek, Petr, et al. "Re: High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer. Initial Outcomes of a United States Series." European urology vol. 79,4 (2021): 554-555. doi: https://doi.org/10.1016/j.eururo.2020.11.039
Macek P, Sanchez-Salas R, Cathelineau X. Re: High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer. Initial Outcomes of a United States Series. Eur Urol. 2021 Apr;79(4):554-555. doi: 10.1016/j.eururo.2020.11.039. Epub 2020 Dec 09. PMID: 33308906.
Copy Download .nbib Format: NLM
Current state of image-guided focal therapy for prostate cancer.

World journal of urology

Tourinho-Barbosa RR, Wood BJ, Abreu AL, Nahar B, Shin T, Guven S, Polascik TJ.
PMID: 32444886
World J Urol. 2021 Mar;39(3):701-717. doi: 10.1007/s00345-020-03254-4. Epub 2020 May 22.

PURPOSE: To review the current evidence regarding protocols and outcomes of image-guided focal therapy (FT) for prostate cancer (PCa).METHODS: A literature search of the latest published studies assessing primary FT for PCa was carried out in Medline and Cochrane...

Cite
Tourinho-Barbosa RR, Wood BJ, Abreu AL, et al. Current state of image-guided focal therapy for prostate cancer. World J Urol. 2020;39(3):701-717doi: 10.1007/s00345-020-03254-4.
Tourinho-Barbosa, R. R., Wood, B. J., Abreu, A. L., Nahar, B., Shin, T., Guven, S., & Polascik, T. J. (2021). Current state of image-guided focal therapy for prostate cancer. World journal of urology, 39(3), 701-717. https://doi.org/10.1007/s00345-020-03254-4
Tourinho-Barbosa, Rafael R, et al. "Current state of image-guided focal therapy for prostate cancer." World journal of urology vol. 39,3 (2021): 701-717. doi: https://doi.org/10.1007/s00345-020-03254-4
Tourinho-Barbosa RR, Wood BJ, Abreu AL, Nahar B, Shin T, Guven S, Polascik TJ. Current state of image-guided focal therapy for prostate cancer. World J Urol. 2021 Mar;39(3):701-717. doi: 10.1007/s00345-020-03254-4. Epub 2020 May 22. PMID: 32444886.
Copy Download .nbib Format: NLM
Re: Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial.

European urology

Sanchez-Salas R.
PMID: 27613062
Eur Urol. 2017 Feb;71(2):301-302. doi: 10.1016/j.eururo.2016.08.064. Epub 2016 Sep 06.

No abstract available.

Cite
Sanchez-Salas R. Re: Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. Eur Urol. 2016;71(2):301-302doi: 10.1016/j.eururo.2016.08.064.
Sanchez-Salas, R. (2017). Re: Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. European urology, 71(2), 301-302. https://doi.org/10.1016/j.eururo.2016.08.064
Sanchez-Salas, Rafael. "Re: Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial." European urology vol. 71,2 (2017): 301-302. doi: https://doi.org/10.1016/j.eururo.2016.08.064
Sanchez-Salas R. Re: Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. Eur Urol. 2017 Feb;71(2):301-302. doi: 10.1016/j.eururo.2016.08.064. Epub 2016 Sep 06. PMID: 27613062.
Copy Download .nbib Format: NLM
Surgery for oligometastatic prostate cancer: Where are we going?.

Actas urologicas espanolas

Alvarez-Maestro M, Gomez Rivas J, Moschini M.
PMID: 34330693
Actas Urol Esp (Engl Ed). 2021 Sep;45(7):479-480. doi: 10.1016/j.acuroe.2021.06.006. Epub 2021 Jul 28.

No abstract available.

Cite
Alvarez-Maestro M, Gomez Rivas J, Moschini M. Surgery for oligometastatic prostate cancer: Where are we going?. Actas Urol Esp (Engl Ed). 2021;45(7):479-480doi: 10.1016/j.acuroe.2021.06.006.
Alvarez-Maestro, M., Gomez Rivas, J., & Moschini, M. (2021). Surgery for oligometastatic prostate cancer: Where are we going?. Actas urologicas espanolas, 45(7), 479-480. https://doi.org/10.1016/j.acuroe.2021.06.006
Alvarez-Maestro, M, et al. "Surgery for oligometastatic prostate cancer: Where are we going?." Actas urologicas espanolas vol. 45,7 (2021): 479-480. doi: https://doi.org/10.1016/j.acuroe.2021.06.006
Alvarez-Maestro M, Gomez Rivas J, Moschini M. Surgery for oligometastatic prostate cancer: Where are we going?. Actas Urol Esp (Engl Ed). 2021 Sep;45(7):479-480. doi: 10.1016/j.acuroe.2021.06.006. Epub 2021 Jul 28. Spanish. PMID: 34330693.
Copy Download .nbib Format: NLM
Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19.

Annals of surgical oncology

Sokas C, Kelly M, Sheu C, Song J, Welch HG, Bergmark R, Minami C, Trinh QD.
PMID: 34170430
Ann Surg Oncol. 2021 Dec;28(13):8688-8696. doi: 10.1245/s10434-021-10319-0. Epub 2021 Jun 25.

BACKGROUND: During the height of the coronavirus disease 2019 (COVID-19) pandemic, elective surgeries, including oncologic surgeries, were delayed. Little prospective data existed to guide practice, and professional surgical societies issued recommendations grounded mainly in common sense and expert consensus,...

Cite
Sokas C, Kelly M, Sheu C, et al. Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19. Ann Surg Oncol. 2021;28(13):8688-8696doi: 10.1245/s10434-021-10319-0.
Sokas, C., Kelly, M., Sheu, C., Song, J., Welch, H. G., Bergmark, R., Minami, C., & Trinh, Q. D. (2021). Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19. Annals of surgical oncology, 28(13), 8688-8696. https://doi.org/10.1245/s10434-021-10319-0
Sokas, Claire, et al. "Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19." Annals of surgical oncology vol. 28,13 (2021): 8688-8696. doi: https://doi.org/10.1245/s10434-021-10319-0
Sokas C, Kelly M, Sheu C, Song J, Welch HG, Bergmark R, Minami C, Trinh QD. Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19. Ann Surg Oncol. 2021 Dec;28(13):8688-8696. doi: 10.1245/s10434-021-10319-0. Epub 2021 Jun 25. PMID: 34170430; PMCID: PMC8231084.
Copy Download .nbib Format: NLM
Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Giannarini G, Gandaglia G, Montorsi F, Briganti A.
PMID: 24687824
J Clin Oncol. 2014 May 01;32(13):1299-301. doi: 10.1200/JCO.2013.54.8214. Epub 2014 Mar 31.

No abstract available.

Cite
Giannarini G, Gandaglia G, Montorsi F, et al. Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?. J Clin Oncol. 2014;32(13):1299-301doi: 10.1200/JCO.2013.54.8214.
Giannarini, G., Gandaglia, G., Montorsi, F., & Briganti, A. (2014). Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(13), 1299-301. https://doi.org/10.1200/JCO.2013.54.8214
Giannarini, Gianluca, et al. "Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 32,13 (2014): 1299-301. doi: https://doi.org/10.1200/JCO.2013.54.8214
Giannarini G, Gandaglia G, Montorsi F, Briganti A. Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?. J Clin Oncol. 2014 May 01;32(13):1299-301. doi: 10.1200/JCO.2013.54.8214. Epub 2014 Mar 31. PMID: 24687824.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries